KLRA Kailera Therapeutics
Kailera Therapeutics earnings company data as of 4:48 AM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 11 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by KLRA's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $327M bought by 5 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Rtw Investments, LP 10% owner, +1 joint filerBuy$8M 500,000 shares at $16.00 +4.9% to stakeTraded Apr 20 Filed Apr 22
-
Bain Capital Investors LLC 10% owner, +4 joint filersBuy$134M 8,398,438 shares at $16.00 +47% to stakeTraded Apr 20 Filed Apr 20
-
Adam Koppel DirectorBuy$25M 1,562,500 shares at $16.00 +7.4% to stakeTraded Apr 20 Filed Apr 20
Also filed in the last 12 months, not counted as buying or selling: 9 conversions and 1 option exercise.
SEC filings
Recent issuer filings from EDGAR, 13 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13D | — | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| 8-K | 5.03,8.01,9.01 | Filing Doc | |
| 424B4 | Filing Doc | ||
| S-1/A | Filing Doc | ||
| S-1 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.